Latest Research And Development News

xReality Group has identified unaudited adjustments that deepen its FY26 loss by $5.79 million and cut net assets from $14.0 million to $6.7 million. Customer revenue and cash flow are unchanged, but trading is suspended until the audit and amended accounts are completed.

Stakk Limited (ASX:SKK) delivered a sharp FY2026 revenue increase and moved to audited operating profitability, but its next test is considerably larger: integrating ParaScript while servicing new debt and converting contracted revenue into cash. The company is targeting A$55.2 million of pro forma revenue and A$18.5 million of EBITDA in FY2027.

Prophecy International’s revenue fell 15% and its statutory loss widened to $7.9 million in FY26, leaving the software group with $1 million in cash and negative net assets. A major restructure, new debtor finance facility and AI product launch offer a recovery plan, but the auditor has warned of material uncertainty around the company’s ability to continue as a going concern.

ClearVue Technologies reported just A$108,484 of FY2026 revenue against an A$11.86 million loss, while consuming A$8.69 million in operating cash. The solar-glazing developer says certifications, international partners and an 80-project pipeline have strengthened its platform, but the next test is converting those assets into cash revenue.

FBR has cut its annual loss dramatically and moved its first Mantis welding robot into commissioning, but year-end cash of just A$27,814 leaves the company dependent on fundraising, tax funding and successful delivery. Its audited accounts flag a material uncertainty over whether the robotics developer can continue as a going concern.

International Graphite has moved its graphite processing strategy from plans towards construction and joint ventures, but the FY2026 annual report shows the company remains loss-making and reliant on external funding. Collie is scheduled for building completion in Q2 2027, while the proposed European hub still requires financing and development work.

BauMart Holdings returned to profit in FY2026 as revenue surged, but the result came alongside negative operating cash flow, net liabilities and an auditor-flagged material uncertainty over its ability to continue as a going concern. A post-year-end $244,463 placement provides near-term funding, while receivables collection remains critical.

Pure Foods Tasmania has warned of a material uncertainty over its ability to continue as a going concern after reporting an $8.6 million FY2026 loss, negative cash and a breach of its Commonwealth Bank covenant. The company expects its existing funding facilities to fall short from approximately February 2027, with further equity funding still uncommitted.

Yojee enters FY27 with 12 signed MOSAIC customer agreements and $10.45 million in fresh funding, but the freight software company is still loss-making and yet to generate meaningful MOSAIC revenue. Management expects initial billings in the December quarter as it works to convert signed customers into live, billable usage.

Quantum Graphite has moved Uley 2 into front-end engineering and design, renewed key mining leases and formalised its downstream structure with Sunlands Pure Group. But the company ended FY2026 with just $210,710 in cash, $10.50 million in borrowings and an auditor-documented material uncertainty over its ability to continue as a going concern.

Radiopharm Theranostics reported a A$56.3 million comprehensive loss for fiscal 2026, with operating cash outflows rising to A$52.8 million and cash falling to A$4.1 million. The company says further funding is required, while auditors flag a material uncertainty over its ability to continue as a going concern.

Clarity Pharmaceuticals is approaching pivotal Phase III readouts for its prostate cancer imaging agent, backed by AUD178.3 million in liquid assets. The radiopharmaceutical developer remains deeply loss-making, but expanded manufacturing capacity and early clinical signals are pulling its commercial ambitions into sharper focus.